Combined Cancer Immunotherapy Based on Immunostimulant Monoclonal Antibodies

Clínica Universidad de Navarra is playing key role in the development of clinical trials of different immunomodulatory agents based on monoclonal antibodies (immunostimulant monoclonal antibodies). These agents act by depressing inhibitory mechanisms of the immune system (e.g., anti-PD-1 and anti-CTLA-4) or by acting as agonists on receptors that activate the immune system (CD137, OX40, LAG-3). In order to optimize their antitumor effects, we are testing combinations in treatment strategies that look for therapeutic effects of greater synergy by combining the following: (i) several agents of this type, (ii) intra-tumor injection of pro-immunogenic substances or viral vectors, (iii) transitory adoptive-cell therapy with genetically modified T lymphocytes by means of electroporation of synthetic mRNA and siRNA, and (iv) external radiotherapy and brachytherapy strategies. A large part of our efforts are focused on understanding the molecular and cellular mechanisms involved in the synergetic effects achieved by means of these treatments and in their translation to pioneering clinical trials in patients with advanced cancer. To do this, we have animal models and models of valuable samples from patients treated in clinical trials that are in progress or that have already been completed.

Active projects

  • Inmunoterapia del cáncer mediante anticuerpos coestimuladores tumor-específicos

    Convocatoria: Desarrollo e Innovación Orientada a los Retos de la Sociedad, en el marco del Plan Estatal de Investigación Científica y Técnica y de Innovación 2013-2016.

    Objetivo Temático Programa Operativo: Promover el desarrollo tecnológico, la innovación y la investigación de calidad.

    Título: Inmunoterapia del cáncer mediante anticuerpos coestimuladores tumor-específicos.

    IP: Ignacio Melero Bermejo.

    Fecha Inicio: 01/10/2016 Fecha Fin: 31/12/2019

    Ref: RTC-2016-5118-1

    Duración: 4 años.

    Financiador: Ministerio de Economía y Competitividad.

    Importe Concedido: 61.407,50€. Importe Financiado: 52.546,00€.

"Immunostimulant monoclonal antibodies are therapeutic tools that supply the cells of the immune system with instructions for eradicating tumors. They act by interfering with inhibitory receptors or by stimulating activator receptors.", Dr. Ignacio Melero

More information:


Cibeles Pinto
Avda. Pío XII, 55
31008 Pamplona

+34 948 194 700 Ext. 4012